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Epidemiological studies show that atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality worldwide
and point to gender diﬀerences with ageing males being at highest risk. Atherosclerosis is a complex process that has several risk
factors and mediators. Hypogonadism is a commonly undiagnosed disease that has been associated with many of the events, and
riskfactors leading to atherosclerosis. The mechanistic relations between testosterone levels, atherosclerotic events, and riskfactors
are poorly understood in many instances, but the links are clear. In this paper, we summarize the research journey that explains
the link between hypogonadism, each of the atherosclerotic events, and risk factors. We look into the diﬀerent areas from which
lessons could be learned, including epidemiological studies, animal and laboratory experiments, studies on androgen deprivation
therapypatients,andstudiesontestosterone-treatedpatients.Weﬁnishbyprovidingrecommendations fortheclinician and needs
for future research.
1.Introduction
Atherosclerotic cardiovascular disease is the leading cause of
mortality and morbidity worldwide. With the advances in
medicine leading to increasingly ageing populations, cardio-
vascular disease appears as the number one noncommunica-
ble cause of death worldwide, and it is on the rise [1]. Athe-
rosclerosis is a diﬀuse disease process with many risk factors.
Age, dyslipidemia, hypertension, obesity, and diabetes are
some of the risk factors that have been extensively studied.
Additionally, males have double the risk of females [2]. This
gender diﬀerence was initially thought to be exclusively due
to female atheroprotective hormones. Nonetheless, a large
part of this gender susceptibility diﬀerence is due to the de-
creasing androgen levels in ageing men, who are at highest
risk for atherosclerosis [3].
Hypogonadal hypogonadism is a commonly undiag-
nosed disease in the general population with symptoms such
asdecreasedlibido,fatigue,musclelossandincreasedvisceral
fat, osteoporosis, reduced energy, and mood changes. More
importantly, hypogonadism is associated with increased ath-
erosclerosis. This relationship is very complex and hence is a
subject for tremendous amount of research. Hypogonadism
has been associated with all the risk factors of atherosclerosis
mentioned above and contributes to the increased suscepti-
bility of men to the disease [4]. The causality relation, how-
ever,isstillcontroversialduetothepoorlyunderstoodmech-
anisms. Also very often, the relationship between hypogo-
nadism and the atherosclerotic risk factor is bidirectional.
More importantly, hypogonadism has been implicated in the
pathogenesis of atherosclerosis and the susceptibility of the
myocardium to ischemia [5]. Various animal and in-vitro
studies have elucidated the pathways through which testos-
terone aﬀects vascular and myocardial health. Although a
lot of research progress has been made in that regard, the
story is still far from being complete with many statistical
associations in men with poorly understood mechanisms. As
androgen deﬁciency enters the arena as a new cardiovascular
risk factor, the translation of these ﬁndings into the clinic
remains a challenging task due to the lack of evidence from
large randomized clinical trials that could recommend
testosterone treatment to prevent cardiovascular disease.
Given the complexity of the issue, this paper aims to deﬁne
all the directions of research in the ﬁeld from which lessons
could be learned, to connect all the lines between hypogo-
nadismandatherosclerosisandthendwelloneachtoexplain2 International Journal of Endocrinology
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Figure 1: The lines connecting hypogonadism and atherosclerosis. Hypogonadism has been associated with several risk factors of athe-
rosclerosis including obesity, Type II DM, dyslipidemia and hypertension. The relation of hypogonadism with Type II DM and obesity is
most likely bidirectional. All risk factors are interrelated, and the ultimate result is increased atherosclerosis. This has been well studied in
epidemiological studies, which associated low testosterone levels with increased IMT, a known marker or early atherosclerosis. Hypogonad-
ism also contributes to the events leading to atherosclerosis by increasing inﬂammation and aﬀecting endothelial function, and several other
cellular mechanisms involved in the pathogenesis of atherosclerosis. In addition, low testosterone increases the susceptibility to myocardial
ischemia. Erectile dysfunction is a symptom of hypogonadism, but also an end result of atherosclerosis and a predictor of CAD.
the evidence-so-far for that link. Finally, the paper provides
a synthesis for the clinician and researcher as to what could
be currently implemented in the clinic and what research
remains to be done.
2.Connectingthe Lines
Figure 1 shows all the links between hypogonadism and ath-
erosclerosis. Hypogonadism has been associated with several
riskfactorsofatherosclerosis.Ahypogonadalstatestimulates
visceral fat formation and central obesity results. Low testos-
teronehasalsobeenassociatedwiththemetabolicsyndrome,
insulin resistance, and type II diabetes mellitus [4]. An un-
favorable lipid proﬁle and hypertension have also been asso-
ciated with hypogonadism [6]. The “egg and the chick” rule
prevails for the relation of each of these risk factors with
hypogonadism, and most likely the relation is bidirectional.
Ontheotherhand,hypogonadismhasbeenimplicatedinthe
pathogenesis of atherosclerosis, through modulating inﬂam-
mation as well as vascular endothelial function [4]. Some of
these eﬀects are modulated by visceral fat, which acts itself as
an endocrine organ secreting substances that are implicated
in the pathogenesis of atherosclerosis. Testosterone also has
direct eﬀects on the myocardium, and various studies have
linked a hypogonadal state to myocardial susceptibility to
ischemia [5]. Intima-Media Thickness (IMT) is a marker of
atherosclerosis, and various studies have shown an inverse
relationship between testosterone and IMT [7]. Finally, erec-
tile dysfunction (ED) has a vascular element and an endo-
crine element. ED is a symptom of hypogonadism due to low
testosterone. At the same time, ED can be a result peripheral
vascular disease in cases of atherosclerosis. All these links are
depicted in Figure 1. We aim in this paper to simplify this
complexity by discussing the evidence in each connecting
line.
3. Research Directions
Initial observation studies in the late 19th century by Brown-
Sequard on the “rejuvenating elixir” extracted from dog and
guinea pig testicles [8] led to the discovery of testosterone in
the1930s[9].Sincethen,testosteronehasbeentremendously
studied in health and disease, yet the ability of this substance
to prolong life remains a mystery. The relationship of testo-
sterone to atherosclerosis is an area where this hormone can
tremendously aﬀect survival, and this is why it has been ex-
tensively studied. Current evidence on the relation of hypog-
onadism to atherosclerosis comes from diﬀerent directions
of research.
3.1.EpidemiologicalStudies. Giventheknownanabolicfunc-
tion of testosterone and its eﬀect on increasing muscle and
decreasing fat mass, numerous epidemiological and popu-
lation studies correlated testosterone levels with risk factorsInternational Journal of Endocrinology 3
of atherosclerosis, such as obesity, insulin resistance, and an
unfavorable lipid proﬁle. Numerous correlations were also
found between testosterone levels and markers of atheroscle-
rosis, whether imaging-related markers such as Intima-Med-
ia Thickness (IMT) or the presence of plaques and atheroma
size or inﬂammatory markers. Furthermore, studies found
aninverserelationbetweentestosteronelevelsandpremature
coronary artery disease (CAD) among a list of other cardio-
vascular-related outcomes including mortality.
3.2. Animal Studies. In order to investigate the pathophysi-
ology behind the ﬁndings of epidemiological studies, basic
science laboratory research is essential. The focus is to look
at the pathways whereby testosterone aﬀects the risk factors
andtheeventsleadingtoatherosclerosis.Withinthatcontext,
most of the lessons were learned from experiments on ani-
mals. In one recent study for instance, the role of the andro-
gen receptor (AR) on atherosclerosis was studied in mice.
Atherosclerosis in AR knockouts was compared to wild type
conﬁrming the presence of both an AR-dependent and an
AR-independent pathway for atheroprotection by testostero-
ne [10]. Animal studies are also crucial in looking at the ef-
fectsofexogenoustestosteroneadministrationonatheroscle-
rosis. Testosterone can be administered in any dose, and
atherosclerosis lesions can be assessed pathologically. In one
recent study, dihydrotestosterone suppressed foam cell for-
mation and attenuated atherosclerosis development in rab-
bits [11].
3.3. Basic Science Research. Apart from animal studies, basic
science is carried on cell lines and using cellular and mole-
cular techniques to decipher the actions of testosterone on
the cell. In one instance, the eﬀe c to ft e s t o s t e r o n ei ss t u d i e d
on endothelial cells in-vitro, and in another, the expression
of inﬂammatory markers is studied in cell lines. Such basic
science research is essential to corroborate clinical observa-
tions on humans and to further understand the mechanisms
leading to the observed eﬀect.
3.4. Androgen Deprivation Therapy. Androgen deprivation
therapy (ADT) is a commonly used treatment in prostate
cancer patients based on the known role of androgens in
stimulatingtheprostate.Prostatecanceristhemostcommon
cancer in men, and ADT was shown to be eﬀective in im-
proving survival and quality of life [12]. The use of ADT in
prostate cancer is on the rise, and it was estimated in 2005
that half a million Americans are on ADT [13]. It is usually
achieved medically using GnRH agonists or antagonists and
less commonly surgically by orchiectomy. The desired serum
testosterone levels after ADT are usually six times lower than
the lower normal in normal young men [14]. Such medically
induced hypogonadism constitutes a natural population
where the eﬀects on atherosclerosis have been studied. Many
prospective studies on ADT-treated men have shown in-
creased fat mass and diﬀerent metabolic and cardiovascular
perturbations [15].
3.5. Testosterone-Treated Patients. On the other side of the
spectrum,lessons could be learned from testosterone-treated
patients for a conﬁrmed diagnosis of hypogonadism. After
the clinician suspects hypogonadism, making the diagnosis
is straightforward with serum testosterone levels being the
singlemostimportantdiagnostictest.Onceasubnormalser-
um testosterone concentration is conﬁrmed, treatment with
exogenous testosterone is indicated. Numerous studies have
been conducted on testosterone-treated patients and have
documentedimprovementofcardiovascularriskoroutcome
measures in prospective studies or better outcomes than age-
matched controls in cross-sectional studies. These studies
also look into the diﬀerent types, doses, and delivery modes
of testosterone in terms of improvement of cardiovascular-
related outcomes and frequency of adverse eﬀects.
3.6. Randomized Clinical Trials. Randomized clinical trials
(RCTs) are the needed tool to allow recommending testos-
teronetreatmenttopreventortreatatherosclerosis.Thisgoal
is still far from reach, with the current literature being poor
in large well-designed RCTs that can provide solid evidence.
A systematic review and meta-analysis was performed in
2007, and it reported only 30 RCTs, which mostly had small
numbers, poor methodology, and inconsistent results [16].
More recently, two RCTs from Italy and Moscow with 50
and 184 subjects, respectively, showed improved indicators
oftheMetSanddecreaseinsomeinﬂammatorymarkerswith
testosterone treatment as compared to placebo [17, 18].
4. Hypogonadism and Atherosclerotic
Risk Factors
We already established that hypogonadism has been associ-
ated with several risk factors of atherosclerosis. The relation-
ship between testosterone levels and the risk factor is fre-
quently bidirectional, and the diﬀerent risk factors are often
interrelated. We choose in this paper to discuss four main
risk factors whose relations with hypogonadism have been
well studied.
4.1. Type II Diabetes Mellitus, Insulin Resistance, and the Met-
abolic Syndrome. Type II Diabetes Mellitus (DM II) is one of
the most serious risk factors of atherosclerosis. Several epi-
demiological studies conﬁrmed that low testosterone is asso-
ciatedwithDM IIand theMetabolic Syndrome (MetS).Even
after age-adjustment, cross-sectional studies showed signiﬁ-
cantly lower testosterone levels in DM II patients compared
to normal controls [19, 20]. Other studies also showed simi-
lar associations between low testosterone and the MetS [21,
22]. In prospective studies, low testosterone predicted future
development of DM II and the MetS [23]. In most of these
studies, total testosterone is more associated with DM II and
the MetS than free testosterone. This is mostly because the
relation is mediated by low levels of Sex Hormone-Binding
Globulin(SHBG),whichleadtoalowtotaltestosterone.Low
SHBG has been independently associated with insulin resis-
tance [24], and it has been suggested that SHBG might have4 International Journal of Endocrinology
a direct causing role of insulin resistance [25]. Another evi-
dence comes from prostate cancer patients who are on ADT.
These patients have a higher prevalence of insulin resistance
and hyperglycemia as well as higher incidence of DM II
[26]. On the other hand, testosterone treatment of DM II
p a t i e n t sr e s u l t e di nf a v o r a b l eo u t c o m e ss u c ha si m p r o v e d
glycemic control [27] and decreased need for insulin in in-
sulin-dependentpatients.[28]Thereisalsoadose-eﬀectrela-
tionship between the dose of testosterone used and degree of
insulin resistance [29]. The TIMES2 study recently showed
that six-month treatment with transdermal testosterone of
hypogonadal men with DM II and/or MetS resulted in im-
proved glycemic control, body composition, cholesterol lev-
els,lipoproteina,anderectiledysfunctionascomparedtothe
control group [30]. More importantly, there was no signiﬁ-
cantdiﬀerenceinthefrequencyofadverseeventsbetweenthe
two groups and the majority of the adverse events were mild
or moderate [30]. It has been well established that the favor-
able outcomes of higher testosterone in DM II patients are
due to improved insulin resistance, but there has also been
little evidence from animal studies on a direct eﬀect of testo-
sterone on the pancreas [31]. This is contradicted, however,
by the lack of association between hypogonadism and Type
I Diabetes Mellitus (DM I) suggesting that the eﬀect of low
testosterone is not on hyperglycemia and the pancreas per se.
A large part of the association between hypogonadism and
the MetS is due to the eﬀect of low testosterone on adipocyte
biology and subsequent obesity, which contributes to all the
features of the MetS such as insulin resistance, dyslipidemia,
and hypertension.
4.2. Obesity and Increased Adiposity. Obesity is strictly in-
volved in the pathophysiology of the relationship between
hypogonadism and DMII or MetS. Furthermore, the rela-
tionshipofobesityandinsulinresistancewithhypogonadism
is most probably bidirectional. The best evidence of in-
creased adiposity in hypogonadism comes from ADT pa-
tients who accumulate body fat within three months of
startingtreatment[32].IncidentDMIIisalsohigherinADT
patients [33]. Additional evidence comes from testosterone-
treated patients in whom reduction of fat mass has been
documented[34].Theincreasedvisceralfatthataccumulates
in hypogonadism serves as an endocrine organ that releases
inﬂammatory cytokines that contribute to insulin resistance,
DM II and the MetS [35]. It has also been suggested that
androgens not only attenuate adipogenesis, but also inﬂam-
mation per se [36]. This is very important in terms of vascu-
lar health and the direct eﬀects of testosterone on the events
leading to atherosclerosis as will be discussed in a subsequent
section of this paper. The reverse relation of obesity and
hypogonadism also holds true. Testosterone levels correlate
inversely with weight changes [37, 38] and the MetS predicts
future incidence of hypogonadism [39]. This relation is in
its turn potentially mediated by increased release of inﬂam-
matory cytokines, which inhibit the hypothalamo-pituitary-
gonadal axis at diﬀerent levels [40]. Adipose tissue also con-
tainsaromatase,whichconvertstestosteroneto17β-estradiol
levels. Estradiol seems to inhibit luteinizing hormone secre-
tion since treatment of obese men with aromatase inhibitors
increases testosterone levels [41]. In summary, obesity can
cause hypogonadism, and hypogonadism can cause obesity,
and in both cases a state of increased visceral fat is a major
risk factor for atherosclerosis, whether through a direct eﬀect
on the vasculature or through increasing the incidence and
magnitude of other risk factors of atherosclerosis such as in-
sulin resistance, dyslipidemia, and hypertension. For further
reading on the link between obesity and hypogonadism, we
suggest consulting the recent reviews by Saad and Gooren
and Traish et al. [42, 43].
4.3.Dyslipidemia. Lipid deliveryto the vesselwallisa crucial
component of the pathophysiology of atherosclerosis. This
is why an unfavorable lipid proﬁle is another major indepen-
dent risk factor of atherosclerosis. Epidemiological studies,
studies on testosterone-treated patients, and studies on ADT
patients showed that low testosterone results in an unfavora-
ble lipid proﬁle. Such a proﬁle is usually an increase in tri-
glycerides,totalcholesterol,LDL,andoxidizedLDLandade-
creaseinHDL[6].Alltheseresultinendothelialdysfunction,
oxidative stress, and inﬂammation, all of which are mecha-
nisticprocessesinatherosclerosis.Ithasalsobeenshownthat
an unfavorable lipid proﬁle can contribute to the develop-
ment of the MetS and DM II [40, 44]. Cross-sectional studies
have conﬁrmed that total and LDL cholesterol inversely
c o r r e l a t ewi t ht e s t o s t e r o n el e v e l s[ 45–47]. Testosterone treat-
ment in numerous studies also resulted in a decrease in total
and LDL cholesterol [48–50]. On the other hand, HDL pos-
itively correlates with testosterone levels in cross-sectional
studies [51], yet evidence from the eﬀects of testosterone
treatment on HDL remains controversial [52–54]. Lipopro-
tein a is an established risk factor of atherosclerosis [55]. In a
recent study on ageing hypercholesterolemic men, clinically
signiﬁcant elevations of lipoprotein a were found to be more
prevalent in men with low testosterone [56]. We had also
mentioned that the testosterone treatments of DMII/MetS
patients in the TIMES2 study resulted in lower lipoprotein
a[ 30]. Mechanistic studies have suggested that the change in
lipid proﬁle is related to increased adiposity in hypogonadal
men, with subsequent increase in estradiol levels due to aro-
matization. Estradiol decreases testosterone levels and at the
sametimecanresultintheunfavorablelipidproﬁlediscussed
[57]. Increased HDL can be explained in this context by the
increased estradiol levels, given the reports of higher HDL in
women compared to men [58]. There seems to be a vicious
cycle involving hypogonadism, obesity and the unfavorable
metabolic proﬁle. This proﬁle of dyslipidemia, insulin resis-
tance, and subsequent DM II perpetuates the metabolic syn-
drome through increased adiposity, which results in further
decrease in testosterone levels (Figure 2).
4.4. Hypertension. Hypertension is an important risk factor
for atherosclerosis due to its involvement in the pathophysi-
ologyofvasculardysfunctionthroughendothelial cellinjury.
Hypertension is yet another risk factor that has been associ-
ated with low testosterone levels [59]. This association might
sound counter-intuitive given evidence that anabolic andro-
gens used mostly in young men for body-building purposesInternational Journal of Endocrinology 5
- Inﬂammatory cytokines inhibit the
hypothalamo-pituitary-gonadal axis
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Figure 2: The vicious cycle of hypogonadism, obesity, and dyslipidemia. Low testosterone can cause obesity and fat accumulation, which
results in dyslipidemia and further deposition of visceral fat. Obesity can also decrease testosterone levels through conversion of aromatase
to estradiol in the adipose tissue and through the release of inﬂammatory cytokines that can inhibit the hpothalamo-pituitary-gonadal axis
at multiple levels.
increase the risk of hypertension [60]. However, studies have
suggested that replenishment of testosterone to normal levels
in hypogonadal men results in decreased blood pressure [53,
61]. Studies to identify an androgen-related-independent
pathway for these improvements in blood pressure are lack-
ing, and it is very probable that the observed improvements
in blood pressure in these testosterone-treated men are due
to the decreased adiposity and improved metabolic proﬁle
in general. However, several possible mechanisms have been
suggested to explain the antihypertensive eﬀects of testos-
terone. Kumanov established that plasma endothelin 1 (ET1)
levels are elevated in males with hypogonadism, and testos-
terone treatment decreases ET1 [62, 63]. Another hypothesis
is that testosterone treatment of hypogonadism normalizes
thecontractileRhoA/Rho-kinase(ROCK)signalingpathway,
which is upregulated in hypogonadal states [64]. Other
mechanisms involve decreased nitric oxide synthase (NOS)
and increased asymmetric dimethylarginine (ADMA) in a
hypogonadal state, which are reversed through testosterone
administration [65–67].
5. Hypogonadism and Atherosclerotic Events
Atherosclerosisisacomplicatedprocesswithendothelialdys-
function,oxidativestress,lipiddeposition,andinﬂammation
involved. Direct eﬀects of hypogonadism on the pathophys-
iology of atherosclerosis have been studied in animals and
in-vitro. This has contributed tremendously to our under-
standing of diﬀerent mechanisms through which low testos-
terone can accelerate the atherosclerotic process. Initially, it
washardtoexplainwhytestosteronelevelsinverselycorrelat-
ed with atherosclerosis in men and women in large epide-
miological studies such as the Rotterdam study [68]. This
sounded counter-intuitive since females are known to be
protected from atherosclerosis by estrogens. Androgens on
the other hand have opposite eﬀects, which favor the forma-
tion of atherosclerosis. For instance, testosterone increased
the uptake of cholesterol and formation of the foam cell of
the fatty streak through androgen receptors, which are ex-
pressed in the macrophages [69]. Additionally, testosterone
increased the apoptosis of endothelial cells in men, which
also favors atherosclerosis [70]. Given the results of large
epidemiological studies including the Rotterdam study, all
showing that low levels of testosterone accelerate atheroscle-
rosis, further animal and in-vitro studies were looking into
the mechanisms of that beneﬁt of testosterone to vascular
health. Castrated rabbits that were fed with cholesterol rich
diet had less atherosclerosis when treated with testosterone
[71]. Testosterone supplementation also had an inhibitory
eﬀect on neointima formation and plaque development [72,
73]. The decreased lipid deposition on testosterone supple-
mentation remained in testicular feminized mice that do
not have neither testosterone nor an androgen receptor [74].
This suggested that testosterone acts through an androgen-
receptor-independent pathway. Similar studies yielded more
and more pathways and mechanisms that could explain the
reason behind the association of higher testosterone with
less atherosclerosis. A summary of these mechanisms is elu-
cidated below.
5.1. Inﬂammation. Inﬂammation is an essential component
of atherosclerosis. Inﬂammatory cytokines have a role in
the early development of the atherosclerotic plaque. Various
small studies suggest a role for testosterone in immune mod-
ulation and in decreasing the inﬂammatory component in
atherosclerosis[18,75].Testosteronereplacementinmenhas6 International Journal of Endocrinology
been shown to decrease the levels of endogenous inﬂamma-
tory cytokines implicated in atherosclerosis such as TNF-α,
IL-6, and IL-β [76]. It also increased atheroprotective cyto-
kines such as IL-10 in-vitro as well as in treated hypogonadal
men [76, 77]. C-reactive protein (CRP) is a marker of gen-
eral inﬂammation and is produced by the liver in response
to IL-6. Levels of CRP are used as a marker of atherosclerotic
cardiovascular disease. There seems to be an inverse correla-
tion between CRP and testosterone levels [78, 79]. Testos-
terone replacement has not been shown to aﬀect CRP levels
so far [79, 80]; however, ADT patients showed an increased
CRP in one study [26]. While in-vitro studies on cell lines
serve a great role in identifying the role of testosterone on
expression of inﬂammatory markers, it is hard to make rigid
conclusions from in-vivo studies on men. This is because the
relationship between testosterone levels and inﬂammation
can be confounded by obesity, the MetS, and DM II, all of
which can be caused by hypogonadism and at the same time
can contribute to an increased state of inﬂammation. There-
fore,conclusiveevidencecouldonlycomebycomplementing
observations on men that are duplicated and observed in
large population groups with in-vitro experiments that could
explain the observations in men and can be duplicated by
several basic scientists. This goal is still unreached so far.
5.2. Atherosclerosis Mediating Molecules. Vascular Cell Adhe-
sion Molecule (VCAM) is one of the molecules that permits
themigrationofthemacrophageintothevascularwallandis
hence a major contributor to the formation of the fatty
streak, the initial lesion in atherosclerosis. A study on male
CAD patients showed that VCAM levels inversely correlated
with testosterone levels [81]. However, testosterone replace-
ment in hypogonadal men did not aﬀect serum levels of
VCAM [80]. In-vitro studies on human aortic endothe-
lial cells showed that testosterone inhibits TNF-α-induced
VCAM expression [82]. Further research will need to study
VCAM levels in testosterone replacement patients in larger
doses and over longer periods of treatment.
5.3. Endothelial Function and Vascular Health. Endothelial
function is one important element of vascular health. Any
injury to the endothelium or perturbation in its function can
result in change of vascular tone, hypertension, formation
of a thrombus, or initiation of a new atherosclerotic plaque.
Endothelial dysfunction can be assessed clinically with
surrogate markers such as ﬂow-mediated dilatation in the
brachial artery prior to the development of atherosclerosis.
Cross-sectional studies associated a low testosterone level in
men with endothelial dysfunction [83]. Prospective studies
on testosterone-treated men with CAD showed that testos-
terone was able to improve their endothelial function [84].
Yet, the eﬀect of testosterone replacement of hypogonadal
men on endothelial function has yielded controversial re-
sults, which varied by the dosage form of testosterone [85,
86]. Other studies assessed the eﬀect of testosterone levels on
arterial stiﬀness, which is an independent predictor of CAD
[87]. Epidemiological studies inversely correlated testos-
terone levels with arterial stiﬀness [88], and testosterone
replacement decreased arterial stiﬀness [85]. Endothelin-1,
a vasoconstrictive hormone implicated in hypertension and
CAD, was also studied. Its levels were elevated in hypogo-
nadal men, and it was reduced with testosterone treatment
[89]. Endothelin-1 is produced in aortic endothelial cells,
and it is thought that testosterone upregulates the expression
of the hormone in these cells [89]. Endothelial Progenitor
Cells (EPCs) have also been studied in CAD, and circulating
EPCs were shown to have a role in maintaining the integrity
of the endothelium and were associated with carotid IMT
[90]. Hypogonadal men had low levels of EPCs that could be
increased by exogenous testosterone supplementation [91].
One study looked at the expression and function of the AR
in human EPCs in-vitro as well as the eﬀect of testosterone
on their function [92]. Androgens stimulated human EPC
proliferation and colony formation in concentrations similar
to those present in humans through an AR-dependent
pathway [92].
5.4. Myocardial Health. Although atherosclerosis is a diﬀuse
disease,thebiggestfearisitseﬀectontheheart.Inadditionto
theriskfactorsandeventsinvolvedinCADthatwediscussed,
hypogonadism also negatively aﬀects myocardial health and
can potentially worsen myocardial ischemia in the setting of
CAD. The antianginal properties of testosterone were ﬁrst
reported in the 1940s [93–95]. Depression of the ST segment
ontheelectrocardiogramisamarkerofmyocardialischemia.
Numerous studies have reported decreased anginal episodes
and reduced ST depression on treatment with testosterone
[5, 96, 97]. Although part of these observations is explained
bytheeﬀectoftestosteroneonvasculartonediscussedabove,
it has also been suggested that testosterone has direct eﬀects
on ventricular repolarization of the myocardium [98]. There
is accumulatingevidencethattestosterone protectsfrommy-
ocardial ischemia. Recent small randomized trials showed
improved exercise capacity and increased time to ST depres-
sion as well as decreased frequency of anginal attacks [5, 99].
Another RCT also showed that long-term testosterone treat-
ment can improve exercise capacity and glucose metabolism
in elderly men with stable congestive heart failure (CHF)
[100]; hence, testosterone replacement is being studied as
a treatment for heart failure, given its anabolic eﬀects on
muscle mass and strength [101].
6. Hypogonadism and Atherosclerotic
Surrogate End Points
We discussed so far the lines connecting hypogonadism to
each of the risk factors of atherosclerosis and the events in-
volved in its pathophysiology. Clinical trials and other epi-
demiological studies correlate testosterone levels to diﬀerent
surrogate end points for atherosclerosis. Surrogate end
points are crucial to accurately assess outcome in random-
izedplacebo-controlledtrials.Diﬀerentendpointshavebeen
used with diﬀerential levels of evidence for each.
6.1. Carotid Intima Media Thickness (IMT). Carotid IMT is
one of the most commonly used surrogate end points ofInternational Journal of Endocrinology 7
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Figure 3: Clinical indicators and mechanistic processes involved in the relation of hypogonadism and atherosclerosis at each level of the
pathogenesis of the disease.
atherosclerosis. It is used as a subclinical marker of athero-
sclerosis, and it is a common outcome measure in most stud-
ies on disease progression and eﬀects of treatment including
testosterone supplementation. For instance, low testosterone
levels were related to carotid IMT independent of other
cardiovascular risk factors [7], and testosterone replacement
therapyreducedcarotidIMTindependentlyfromBMI[102].
6.2. Flow Mediated Dilation (FMD). FMD is a measure of
vascular tone and is usually performed in the brachial artery.
An increased FMD indicates endothelial dysfunction, which
has been shown to predict CAD [103]. We have established
earlierthatendothelialdysfunctionandarterialstiﬀnesshave
been associated with hypogonadism. FMD is one surrogate
measure used to assess the endothelial disruption caused by
a low testosterone.
6.3. Erectile Dysfunction (ED). Erectile dysfunction is one of
thesymptomsofhypogonadalhypogonadismaccompanying
the decreased libido caused by decreased serum testoster-
one. However, ED is also an early marker of generalized ath-
erosclerosis and a predictor of cardiovascular events [104].
ED cannot be used as a surrogate end point for atherosclero-
sis in studies looking at testosterone, because the eﬀect itself
is confounded by the low testosterone levels. Nevertheless, it
is important to note that the pathophysiology of ED in hypo-
gonadal men could be due to the direct eﬀe c to fal o wt e s t o -
sterone and also to the atherosclerosis caused by hypogo-
nadism.
6.4. Clinical Events. Clinical events related to morbidity and
mortality from atherosclerosis are also used as end point
measures in studies on hypogonadism and atherosclerosis.
These include cardiovascular events, cerebrovascular events,
and mortality. For the majority of large longitudinal cohort
studies such as the Framingham study, the Caerphilly study,
and the Tromso study, testosterone levels were not associated
with incident cardiovascular disease [105]. Whether testos-
terone levels are associated with the incident strokes and
transient ischemic attacks has been controversial [105].
Whenmortalityistakenasanoutcomemeasureinlongitudi-
nal studies, the ﬁndings have been more consistent. Lower
testosterone levels predict all cause mortality as well as mor-
tality from CVD [105].
7. Safety of Exogenous Testosterone
If testosterone is to be considered for treatment and preven-
tion of atherosclerosis and cardiovascular disease, it has to
be safe. A lot is known about the side eﬀects from the abuse
of androgens in athletes, the most important of which is
sudden death [14]. Other side eﬀects include mainly cardiac
events such as arrhythmias, cardiomypopathy, and myocar-
dial infarctions, as well as noncardiac adverse eﬀects such
aspolycythemia,acne,andhepatotoxicity [14].Nevertheless,
athletes use doses of androgens that are several times higher
than the doses used medically in testosterone replacement
therapy [14]. Hence, such supraphysiological levels of testo-
s t e r o n ec a nc a u s es i d ee ﬀects that are not caused by replace-
ment of testosterone to physiological levels or slightly higher.8 International Journal of Endocrinology
Diﬀerent metanalyses and systematic reviews have looked at
the safety of testosterone treatment when used in the usual
pharmacological doses. Possible adverse eﬀects include in-
crease in prostate events, increase in hemoglobin and hem-
atocrit, and a small decrease in HDL cholesterol, but the evi-
denceisstillpoorandwithunknownclinicalsigniﬁcancedue
to short followup [106–108].
8. Summary
Hypogonadal hypogonadism is a common disease especially
in elderly men who are at high risk of atherosclerotic cardio-
vascular disease. Low testosterone is a risk factor for athero-
sclerosis. Not only does it cause several of its risk factors, but
it also accelerates the events involved in the pathophysiology
of atherosclerosis. Studies have conﬁrmed the link between
testosterone levels and several surrogate end points of ath-
erosclerosis. Diﬀerent clinical indicators of atherosclerosis
have been associated with hypogonadism, and diﬀerent
mechanistic processes involved in atherosclerosis have been
linked to hypogonadism. Figure 3 shows the progression of
atherosclerosis and summarizes the clinical indicators stud-
ied and mechanistic processes involved at each level of the
disease as discussed in this paper.
9. Recommendations for the
Researcher and Clinician
Over the past two decades, the interest in androgens has
stimulated a lot of research that increased our understanding
oftheirroleinatherosclerosis.Evidencecomesfromdiﬀerent
directions of research, yet gaps are still large in diﬀerent
areas, and more research is to be done. Particularly, there is
a need for large randomized placebo-controlled clinical trials
to assess the eﬃciency and safety of testosterone treatment in
healthy men to prevent or delay atherosclerosis. Also more
basic science research is essential to understand the mech-
anisms behind the involvement of testosterone in the risk
factors and events leading to atherosclerosis.
At the moment, testosterone replacement is only recom-
mended for patients with a conﬁrmed diagnosis of hypog-
onadal hypogonadism. Clinicians are highly recommended
to recognize the clinical features of hypogonadism and to
screen for it and treat it to improve quality of life and prevent
atherosclerosis. Current research is not enough to recom-
mend testosterone supplementation for patients who do not
have hypogonadism, in the absence of large randomized
placebo-controlled trials.
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